Literature DB >> 19320592

Low levels of antiretroviral-resistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment.

Charles Kouanfack1, Celine Montavon, Christian Laurent, Avelin Aghokeng, Alain Kenfack, Anke Bourgeois, Sinata Koulla-Shiro, Eitel Mpoudi-Ngole, Martine Peeters, Eric Delaporte.   

Abstract

A cross-sectional study, performed at a routine human immunodeficiency virus (HIV)/AIDS clinic in Cameroon that uses the World Health Organization public health approach, showed low rates of virological failure and drug resistance at 12 and 24 months after initiation of antiretroviral therapy. Importantly, the cross-sectional study also showed that the World Health Organization recommendation for second-line treatment would be effective in almost all patients with HIV drug resistance mutations.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19320592     DOI: 10.1086/597779

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  24 in total

1.  A retrospective survey of HIV drug resistance among patients 1 year after initiation of antiretroviral therapy at 4 clinics in Malawi.

Authors:  Nellie Wadonda-Kabondo; Bethany L Hedt; Joep J van Oosterhout; Kundai Moyo; Eddie Limbambala; George Bello; Ben Chilima; Erik Schouten; Anthony Harries; Moses Massaquoi; Carol Porter; Ralf Weigel; Mina Hosseinipour; John Aberle-Grasse; Michael R Jordan; Storn Kabuluzi; Diane E Bennett
Journal:  Clin Infect Dis       Date:  2012-05       Impact factor: 9.079

2.  HIV-1 genetic diversity and drug resistance among Senegalese patients in the public health system.

Authors:  Moussa Thiam; Halimatou Diop-Ndiaye; Aminata Diaw Diouf; Nicole Vidal; Ousseynou Ndiaye; Ibrahima Ndiaye; Ndeye Fatou Ngom-Gueye; Sada Diallo; Oumy Diop Diongue; Makhtar Camara; Abdoulaye Seck; Souleymane Mboup; Coumba Toure-Kane
Journal:  J Clin Microbiol       Date:  2012-12-12       Impact factor: 5.948

Review 3.  Rates of emergence of HIV drug resistance in resource-limited settings: a systematic review.

Authors:  Kathryn M Stadeli; Douglas D Richman
Journal:  Antivir Ther       Date:  2012-10-10

Review 4.  Viral suppression after 12 months of antiretroviral therapy in low- and middle-income countries: a systematic review.

Authors:  James H McMahon; Julian H Elliott; Silvia Bertagnolio; Rachel Kubiak; Michael R Jordan
Journal:  Bull World Health Organ       Date:  2013-02-21       Impact factor: 9.408

5.  The HIV-1 epidemic: low- to middle-income countries.

Authors:  Yiming Shao; Carolyn Williamson
Journal:  Cold Spring Harb Perspect Med       Date:  2012-03       Impact factor: 6.915

6.  Viral Suppression and HIV Drug Resistance at 6 Months Among Women in Malawi's Option B+ Program: Results From the PURE Malawi Study.

Authors:  Mina Hosseinipour; Julie A E Nelson; Clement Trapence; Sarah E Rutstein; Florence Kasende; Virginia Kayoyo; Blessings Kaunda-Khangamwa; Kara Compliment; Christopher Stanley; Fabian Cataldo; Monique van Lettow; Nora E Rosenberg; Hannock Tweya; Salem Gugsa; Veena Sampathkumar; Erik Schouten; Michael Eliya; Frank Chimbwandira; Levison Chiwaula; Atupele Kapito-Tembo; Sam Phiri
Journal:  J Acquir Immune Defic Syndr       Date:  2017-06-01       Impact factor: 3.731

7.  Increasing rate of TAMs and etravirine resistance in HIV-1-infected adults between 12 and 24 months of treatment: the VOLTART cohort study in Côte d'Ivoire, West Africa.

Authors:  Eugène Messou; Marie-Laure Chaix; Delphine Gabillard; Vincent Yapo; Thomas-d'Aquin Toni; Albert Minga; Martial Guillaume Kouakou; Eric Ouattara; Christine Rouzioux; Christine Danel; Serge P Eholie; Xavier Anglaret
Journal:  J Acquir Immune Defic Syndr       Date:  2013-10-01       Impact factor: 3.731

8.  Prevalence of HIV drug resistance before and 1 year after treatment initiation in 4 sites in the Malawi antiretroviral treatment program.

Authors:  Nellie Wadonda-Kabondo; Diane Bennett; Joep J van Oosterhout; Kundai Moyo; Mina Hosseinipour; Josh Devos; Zhiyong Zhou; John Aberle-Grasse; Thomas R Warne; Clement Mtika; Ben Chilima; Richard Banda; Olesi Pasulani; Carol Porter; Sam Phiri; Andreas Jahn; Debbie Kamwendo; Michael R Jordan; Storn Kabuluzi; Frank Chimbwandira; Mathew Kagoli; Blackson Matatiyo; Austin Demby; Chunfu Yang
Journal:  Clin Infect Dis       Date:  2012-05       Impact factor: 9.079

Review 9.  Monitoring antiretroviral therapy in resource-limited settings: balancing clinical care, technology, and human resources.

Authors:  Mina C Hosseinipour; Mauro Schechter
Journal:  Curr HIV/AIDS Rep       Date:  2010-08       Impact factor: 5.071

10.  Cost-effectiveness of point-of-care viral load monitoring of antiretroviral therapy in resource-limited settings: mathematical modelling study.

Authors:  Janne Estill; Matthias Egger; Nello Blaser; Luisa Salazar Vizcaya; Daniela Garone; Robin Wood; Jennifer Campbell; Timothy B Hallett; Olivia Keiser
Journal:  AIDS       Date:  2013-06-01       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.